Frances E. Carr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Frances E. Carr has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Noelle E. Gillis
University of Minnesota
34 shared publications Jennifer A. Tomczak
31 shared publicationsEric L. Bolf
27 shared publicationsSeth Frietze
26 shared publications- Cole D. Davidson
Department of Pharmacology, Larner College of Medicine, Burlington, Vermont
25 shared publications Lauren Cozzens
25 shared publications
Latest Publications
- 23 October 2025
- Published by The Endocrine Society in Endocrinology
- Vol. 166 (12)
Thyroid Hormone Receptor β Suppresses Cancer Cell Activity by Differential Regulation of Glycogen Metabolism
Anaplastic thyroid cancer (ATC) is one of the most lethal endocrine cancers with no enduring therapies. Thyroid hormone receptor β (TRβ), a recognized tumor suppressor, modulates the transcriptome altering gene expression in numerous intracellular signaling pathways. Our recent studies revealed that TRβ agonism inhibits glycogen metabolism in ATC cells. Our goal in the present study was to delineate the molecular mechanisms by which TRβ regulates glycogen synthesis and breakdown. In ATC cells, activation of TRβ induced changes in expression of genes and proteins in glycogen signaling concordant with downregulation of cancer metabolism. The impact on the cancer cell metabolic phenotype was determined by glycogen levels, cell viability, and reactive oxygen species characterization. Our results revealed that TRβ activation differentially regulates glycogen signaling pathways reflective of the genetic landscape of the cells. This suggests TRβ can suppress tumor growth and progression through multiple steps in glycogen metabolism, giving it a unique and distinct role in fine-tuning the microenvironment of the cell as an internal sensor of the general environment of the cell. These studies reveal the potential of a synergistic effect of TRβ agonism and inhibition of glycogen metabolism in the treatment of aggressive dedifferentiated thyroid cancers.
- 23 October 2025
- Published by The Endocrine Society in Endocrinology
- Vol. 166 (12)
Thyroid Hormone Receptor β Suppresses Cancer Cell Activity by Differential Regulation of Glycogen Metabolism
Anaplastic thyroid cancer (ATC) is one of the most lethal endocrine cancers with no enduring therapies. Thyroid hormone receptor β (TRβ), a recognized tumor suppressor, modulates the transcriptome altering gene expression in numerous intracellular signaling pathways. Our recent studies revealed that TRβ agonism inhibits glycogen metabolism in ATC cells. Our goal in the present study was to delineate the molecular mechanisms by which TRβ regulates glycogen synthesis and breakdown. In ATC cells, activation of TRβ induced changes in expression of genes and proteins in glycogen signaling concordant with downregulation of cancer metabolism. The impact on the cancer cell metabolic phenotype was determined by glycogen levels, cell viability, and reactive oxygen species characterization. Our results revealed that TRβ activation differentially regulates glycogen signaling pathways reflective of the genetic landscape of the cells. This suggests TRβ can suppress tumor growth and progression through multiple steps in glycogen metabolism, giving it a unique and distinct role in fine-tuning the microenvironment of the cell as an internal sensor of the general environment of the cell. These studies reveal the potential of a synergistic effect of TRβ agonism and inhibition of glycogen metabolism in the treatment of aggressive dedifferentiated thyroid cancers.
- 14 July 2025
- Published by The Endocrine Society in Endocrinology
- Vol. 166 (9)
Epigenomic Modulators and Thyroid Hormone Receptor Beta Agonists: A New Paradigm for Tumor Suppression in Thyroid Cancer
The transcription factor thyroid hormone receptor beta (TRβ), a recognized tumor suppressor, interacts with chromatin modifying protein complexes to modulate the transcriptome and induce a tumor suppression gene regulatory network. Recent studies have linked poorly differentiated and anaplastic thyroid cancers to aberrant epigenomic signaling, chromatin accessibility, and gene expression. As no enduring treatments are available for these aggressive thyroid cancers and treatment resistant disease, unveiling the epigenomic co-regulatory proteins mediating TRβ signaling will advance the understanding of the molecular mechanisms of TRβ action to block tumor progression and reveal potential novel therapeutic targets. In this review, we summarize novel findings on the epigenomic landscape in the context of TRβ in thyroid malignancy, including the identification of previously unrecognized TRβ interactors and the mapping of nine distinct functional protein communities that constitute the TRβ interactome in thyroid cells. We also explore how targeting TRβ interactors using existing epigenetic enzyme inhibitors—such as HDAC, LSD1, and BET inhibitors—in combination with TRβ agonists, may work synergistically to reprogram tumor epigenetics and suppress oncogenic transcriptional programs.
- 14 July 2025
- Published by The Endocrine Society in Endocrinology
- Vol. 166 (9)
Epigenomic Modulators and Thyroid Hormone Receptor Beta Agonists: A New Paradigm for Tumor Suppression in Thyroid Cancer
The transcription factor thyroid hormone receptor beta (TRβ), a recognized tumor suppressor, interacts with chromatin modifying protein complexes to modulate the transcriptome and induce a tumor suppression gene regulatory network. Recent studies have linked poorly differentiated and anaplastic thyroid cancers to aberrant epigenomic signaling, chromatin accessibility, and gene expression. As no enduring treatments are available for these aggressive thyroid cancers and treatment resistant disease, unveiling the epigenomic co-regulatory proteins mediating TRβ signaling will advance the understanding of the molecular mechanisms of TRβ action to block tumor progression and reveal potential novel therapeutic targets. In this review, we summarize novel findings on the epigenomic landscape in the context of TRβ in thyroid malignancy, including the identification of previously unrecognized TRβ interactors and the mapping of nine distinct functional protein communities that constitute the TRβ interactome in thyroid cells. We also explore how targeting TRβ interactors using existing epigenetic enzyme inhibitors—such as HDAC, LSD1, and BET inhibitors—in combination with TRβ agonists, may work synergistically to reprogram tumor epigenetics and suppress oncogenic transcriptional programs.
- 28 August 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (10)
TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice
Thyroid hormone receptor beta (TRβ) is a recognized tumor suppressor in numerous solid cancers. The molecular signaling of TRβ has been elucidated in several cancer types through re-expression models. Remarkably, the potential impact of selective activation of endogenous TRβ on tumor progression remains largely unexplored. We used cell-based and in vivo assays to evaluate the effects of the TRβ agonist Sobetirome (GC-1) on a particularly aggressive and dedifferentiated cancer, anaplastic thyroid cancer (ATC). Here we report that GC-1 reduced the tumorigenic phenotype, decreased cancer stem-like cell populations, and induced re-differentiation of the ATC cell lines with different mutational backgrounds. Of note, this selective activation of TRβ amplified the effects of therapeutic agents in blunting the aggressive cell phenotype and stem-cell growth. In xenograft assays, GC-1 alone inhibited tumor growth and was as effective as the kinase inhibitor, Sorafenib. These results indicate that selective activation of TRβ not only induces a tumor suppression program de novo but enhances the effectiveness of anti-cancer agents revealing potential novel combination therapies for ATC and other aggressive solid tumors.
- 28 August 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (10)
TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice
Thyroid hormone receptor beta (TRβ) is a recognized tumor suppressor in numerous solid cancers. The molecular signaling of TRβ has been elucidated in several cancer types through re-expression models. Remarkably, the potential impact of selective activation of endogenous TRβ on tumor progression remains largely unexplored. We used cell-based and in vivo assays to evaluate the effects of the TRβ agonist Sobetirome (GC-1) on a particularly aggressive and dedifferentiated cancer, anaplastic thyroid cancer (ATC). Here we report that GC-1 reduced the tumorigenic phenotype, decreased cancer stem-like cell populations, and induced re-differentiation of the ATC cell lines with different mutational backgrounds. Of note, this selective activation of TRβ amplified the effects of therapeutic agents in blunting the aggressive cell phenotype and stem-cell growth. In xenograft assays, GC-1 alone inhibited tumor growth and was as effective as the kinase inhibitor, Sorafenib. These results indicate that selective activation of TRβ not only induces a tumor suppression program de novo but enhances the effectiveness of anti-cancer agents revealing potential novel combination therapies for ATC and other aggressive solid tumors.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
The thyroid hormone receptor beta (TRβ), a key regulator of cellular growth and differentiation, is frequently dysregulated in cancers. Diminished expression of TRβ is noted in thyroid, breast, and other solid tumors and is correlated with more aggressive disease. Restoration of TRβ levels decreased tumor growth supporting the concept that TRβ could function as a tumor suppressor. Yet, the TRβ tumor suppression transcriptome is not well delineated and the impact of TRβ is unknown in aggressive anaplastic thyroid cancer (ATC). Here, we establish that restoration of TRβ expression in the human ATC cell line SW1736 (SW-TRβ) reduces the aggressive phenotype, decreases cancer stem cell populations and induces cell death in a T3-dependent manner. Transcriptomic analysis of SW-TRβ cells via RNA sequencing revealed distinctive expression patterns induced by ligand-bound TRβ and revealed novel molecular signaling pathways. Of note, liganded TRβ repressed multiple nodes in the PI3K/AKT pathway, induced expression of thyroid differentiation markers, and promoted proapoptotic pathways. Our results further revealed the JAK1–STAT1 pathway as a novel, T3-mediated, antitumorigenic pathway that can be activated in additional ATC lines. These findings elucidate a TRβ-driven tumor suppression transcriptomic signature, highlight unexplored therapeutic options for ATC, and support TRβ activation as a promising therapeutic option in cancers.Implications:TRβ-T3 induced a less aggressive phenotype and tumor suppression program in anaplastic thyroid cancer cells revealing new potential therapeutic targets.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
The thyroid hormone receptor beta (TRβ), a key regulator of cellular growth and differentiation, is frequently dysregulated in cancers. Diminished expression of TRβ is noted in thyroid, breast, and other solid tumors and is correlated with more aggressive disease. Restoration of TRβ levels decreased tumor growth supporting the concept that TRβ could function as a tumor suppressor. Yet, the TRβ tumor suppression transcriptome is not well delineated and the impact of TRβ is unknown in aggressive anaplastic thyroid cancer (ATC). Here, we establish that restoration of TRβ expression in the human ATC cell line SW1736 (SW-TRβ) reduces the aggressive phenotype, decreases cancer stem cell populations and induces cell death in a T3-dependent manner. Transcriptomic analysis of SW-TRβ cells via RNA sequencing revealed distinctive expression patterns induced by ligand-bound TRβ and revealed novel molecular signaling pathways. Of note, liganded TRβ repressed multiple nodes in the PI3K/AKT pathway, induced expression of thyroid differentiation markers, and promoted proapoptotic pathways. Our results further revealed the JAK1–STAT1 pathway as a novel, T3-mediated, antitumorigenic pathway that can be activated in additional ATC lines. These findings elucidate a TRβ-driven tumor suppression transcriptomic signature, highlight unexplored therapeutic options for ATC, and support TRβ activation as a promising therapeutic option in cancers.Implications:TRβ-T3 induced a less aggressive phenotype and tumor suppression program in anaplastic thyroid cancer cells revealing new potential therapeutic targets.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 8: Reintroduction of TRβ Increased Expression of interferon/JAK1/STAT1 Pathway Effectors. A-C) Following 24 hours of treatment with T3 or vehicle, protein levels in SW-EV and SW-TRβ were assessed by western blot. TRβ induced expression of JAK1 and STAT1. Representative western blot depicted. (*p<0.05, n=6) D) STAT1 and IRF1 regulated genes were induced upon overexpression of TRβ and T3 treatment. (n=6, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 8: Reintroduction of TRβ Increased Expression of interferon/JAK1/STAT1 Pathway Effectors. A-C) Following 24 hours of treatment with T3 or vehicle, protein levels in SW-EV and SW-TRβ were assessed by western blot. TRβ induced expression of JAK1 and STAT1. Representative western blot depicted. (*p<0.05, n=6) D) STAT1 and IRF1 regulated genes were induced upon overexpression of TRβ and T3 treatment. (n=6, * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S2 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 2: TRβ Repressed PI3K Signaling. A-I) Expression of cluster 1 differentially expressed genes in the ILK signaling IPA pathway. All genes were repressed by T3 and the level of most of these genes was repressed in the SW-TRβ-T3 condition compared to SW-EV-T3. (n=3, * p0.05) B) AKT phosphorylation was repressed upon overexpression of TRβ in SW1736 cells. (representative blot of 3 experiments).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 2: TRβ Repressed PI3K Signaling. A-I) Expression of cluster 1 differentially expressed genes in the ILK signaling IPA pathway. All genes were repressed by T3 and the level of most of these genes was repressed in the SW-TRβ-T3 condition compared to SW-EV-T3. (n=3, * p0.05) B) AKT phosphorylation was repressed upon overexpression of TRβ in SW1736 cells. (representative blot of 3 experiments).
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 4: TRβ Regulates Expression of lncRNAs in ATC Cells. A) A pairwise comparison between SW-EV-T3 and SW-TRβ-T3 reveals differential expression of both mRNAs and lncRNAs (log2(foldchange)>2 and p<0.05). A total of 350 mRNAs and 28 lncRNAs were differentially expressed. B) Expression levels of the differentially expressed lncRNAs in transcripts per million reads.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 4: TRβ Regulates Expression of lncRNAs in ATC Cells. A) A pairwise comparison between SW-EV-T3 and SW-TRβ-T3 reveals differential expression of both mRNAs and lncRNAs (log2(foldchange)>2 and p<0.05). A total of 350 mRNAs and 28 lncRNAs were differentially expressed. B) Expression levels of the differentially expressed lncRNAs in transcripts per million reads.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S7 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 7: Reintroduction of TRβ Increased Markers of Thyroid Differentiation. Thyroid differentiation markers were significantly induced in SW-TRβ cells treated with T3 (n=3, * p<0.05).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Thyroid Hormone Receptor Beta Induces a Tumor-Suppressive Program in Anaplastic Thyroid Cancer
Supplemental Figure 7: Reintroduction of TRβ Increased Markers of Thyroid Differentiation. Thyroid differentiation markers were significantly induced in SW-TRβ cells treated with T3 (n=3, * p<0.05).